MIRM
Mirum Pharmaceuticals, Inc.NASDAQHealthcare$94.17+2.20%ClosedMarket Cap: $4.73B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
15.35
P/S
9.27
EV/EBITDA
347.82
DCF Value
$-3,572.28
FCF Yield
1.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.8%
Operating Margin
-4.2%
Net Margin
-4.5%
ROE
-8.5%
ROA
-2.8%
ROIC
-3.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $148.9M | 81.0% | $-4.6M | $-5.7M | $-0.12 | — |
| FY 2025 | $521.3M | 80.7% | $-22.1M | $-23.4M | $-0.47 | — |
| Q3 2025 | $133.0M | 80.8% | $2.6M | $2.9M | $0.05 | — |
| Q2 2025 | $127.8M | 81.7% | $-5.0M | $-5.9M | $-0.12 | — |
| Q1 2025 | $111.6M | 79.4% | $-15.2M | $-14.7M | $-0.30 | — |
| Q4 2024 | $99.4M | 77.1% | $-24.2M | $-23.8M | $-0.49 | — |
| FY 2024 | $336.9M | 75.8% | $-87.6M | $-87.9M | $-1.85 | — |
| Q3 2024 | $90.4M | 77.0% | $-12.7M | $-14.2M | $-0.30 | — |
| Q2 2024 | $77.9M | 74.0% | $-24.2M | $-24.6M | $-0.52 | — |
| Q1 2024 | $69.2M | 74.2% | $-26.5M | $-25.3M | $-0.54 | — |
| Q4 2023 | $69.6M | 64.0% | $-32.6M | $-35.7M | $-0.71 | — |
| FY 2023 | $186.4M | 74.8% | $-109.2M | $-163.4M | $-4.00 | — |